Skip to main content

Table 1 Patient background characteristics and pathological response to neoadjuvant chemotherapy

From: Immune microenvironment, homologous recombination deficiency, and therapeutic response to neoadjuvant chemotherapy in triple-negative breast cancer: Japan Breast Cancer Research Group (JBCRG)22 TR

Treatment group   Total A1 A2 B1 B2
Patient number   66 15 18 17 16
Age, years Median 54 44 47 58 56
min.–max. 26–70 31–64 26–63 35–70 41–70
T T1c 13 5 3 2 3
T2 48 9 13 14 12
T3 5 1 2 1 1
N N0 39 7 11 11 10
N1 27 8 7 6 6
Histological grade (B and R) 1 2 1 0 0 1
2 17 2 4 5 6
3 44 11 14 11 8
Unknown 3 1 0 1 1
Ki67 labeling index, % Median 57.7 55 64.2 51.6 50.4
min.–max. 16.2–90 20.2–90 36.4–89.6 20–89 16.2–82
HRD Low 18 0 0 9 9
High 33 15 18 0 0
Unknown 15 0 0 8 7
tBRCA1/2 mutation BRCA1 mutation 6 3 3 0 0
BRCA2 mutation 6 3 3 0 0
No mutation 43 9 12 12 10
Unknown 11 0 0 5 6
pCR Yes 23 10 8 2 3
No 43 5 10 15 13
% 34.8 66.7 44.4 11.8 18.8
  1. A1 group taking paclitaxel + carboplatin, A2 group taking eribulin + carboplatin, B1 eribulin + cyclophosphamide, B2 eribulin + capecitabine, HRD homologous recombination deficiency, tBRCA tumor BRCA, max. maximum, min. minimum, pCR pathological complete response